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REVIEW
The Evolving View of IL-17-Mediated Immunity
in Defense Against Mucocutaneous Candidiasis
in Humans
Bea´ta Solte´sz, Bea´ta To´th, Adrien Katalin Sarkadi, Melinda Erdo˝s,
and La´szlo´ Maro´di
Department of Infectious Diseases and Pediatric Immunology, Faculty of Medicine,
University of Debrecen, Debrecen, Hungary
The discovery of interleukin (IL)-17-mediated immunity has provided a robust framework upon
which our current understanding of the mechanism involved in host defense against mucocu-
taneous candidiasis (CMC) has been built. Studies have shed light on how pattern recognition
receptors expressed by innate immune cells recognize various components of Candida cell wall.
Inborn errors of immunity affecting IL-17+ T cell differentiation have recently been defined, such
as deficiencies of signal transducer and activator of transcription (STAT)3, STAT1, IL-12Rβ1 and
IL-12p40, and caspase recruitment domain 9. Impaired receptor-ligand coupling was identified
in patients with IL-17F and IL-17 receptor A (IL17RA) deficiency and autoimmune polyendocrine
syndrome (APS) type 1. Mutation in the nuclear factor kappa B activator (ACT) 1 was described
as a cause of impaired IL-17R-mediated signaling. CMC may be part of a complex clinical pheno-
type like in patients with deficiencies of STAT3, IL-12Rβ1/IL-12p40 and APS-1 or may be the only
or dominant phenotypic manifestation of disease which is referred to as CMC disease. CMCDmay
result from deficiencies of STAT1, IL-17F, IL-17RA and ACT1. In this review we discuss how recent
research on IL-17-mediated immunity shed light on host defense against mucocutaneous infec-
tion by Candida and how the discovery of various germ-linemutations and the characterization of
associated clinical phenotypes have provided insights into the role of CD4+IL-17+ lymphocytes
in the regulation of anticandidal defense of body surfaces.
Keywords: Candida, interleukin-17, interleukin-17 receptor-mediated signaling, mucocuta-
neous candidiasis disease, pattern-recognition receptors, signal transducer and activator of
transcription
INTRODUCTION
Colonizing Candida may gain access to the circulation and cause invasive blood-
stream infection or organ diseases, including hepato-splenic candidiasis and candida
nephritis [1]. Invasive candidiasis typically occur in hemato-oncology patients and in
those with long-term therapy at intensive care unit [2, 3]. In addition, patients with
chronic granulomatous disease or other primary defects of phagocytic cell function,
as well as those with quantitative deficiency of the phagocytic cell pool also predis-
pose to invasive candidiasis [4, 5]. In contrast, superficial or chronic mucocutaneous
Accepted 3 April 2015.
Address correspondence to La´szlo´ Maro´di, Department of Infectious Diseases and Pediatric
Immunology, Faculty of Medicine, University of Debrecen, Nagyerdei krt 98, 4032, Debrecen,
Hungary. E-mail: lmarodi@med.unideb.hu

D
ow
nl
oa
de
d 
by
 [D
eb
rec
en
 U
niv
ers
ity
], 
[B
eá
ta 
Tó
th]
 at
 00
:23
 07
 A
ug
us
t 2
01
5 
The Evolving View of IL-17-Mediated Immunity in Defense against Mucocutaneous 
candidiasis (CMC) occurs at body surfaces as vulvovaginal, oropharyngeal or
esophageal candidiasis [6–8]. Several primary immunodeficiency disorders (PIDs)
typically characterized by CMC and impaired IL-17-mediated immunity have been
identified recently [9]. CMC in such patients may be part of a complex clinical pheno-
type exemplified by dominant negative signal transducer and activator of transcrip-
tion (STAT)3 deficiency, interleukin (IL)-12Rβ1 and IL-12p40 deficiencies, and au-
toimmune polyendocrine syndrome (APS) type 1 [10–13]. In a subgroup of PIDs, pre-
disposition to superficial candidiasis may be the only or the dominant characteristic
of the underlying genetic disorder (CMC disease, CMCD) [9].The first CMCDwas de-
scribed in 2011 by two groups reporting on 21 unrelated families and 61 patients car-
rying germline missense mutation in the coiled-coil domain (CCD) of STAT1 [14, 15].
One of these groups also reported on impaired differentiation of naı¨ve CD4+ T cells
into IL-17+ lymphocytes due to gain of function (GOF) and gain of phosphorylation
of STAT1 in a large number of patients with CMCD [14]. Subsequently, STAT1 GOF
mutation associated with CMC was found by several groups [16–21]. Primary genetic
defects of the IL-17 cytokine-IL-17R coupling and IL-17R signaling were also reported
as causes of CMCD [22, 23]. In particular, autosomal dominant IL-17F deficiency, au-
tosomal recessive IL-17RAdeficiency, andsignalingdefectdue tomutation in thegene
of nuclear factor kappa B (NF-κB) activator (ACT1) were described. In this review, we
discuss recent developments that have increased our understanding of the immuno-
logical and genetic basis of CMC. Molecular mechanisms that may be involved in the
unique and exceptional tropism of Candida, especially Candida albicans, at the mu-
cosal epithelium will be discussed. Effector functions of CD4+IL17+ T cells will be
reviewed in the context of host defense against infection by Candida at mucosal sur-
faces. Finally, wewill discuss inborn errors of IL-17-mediated immunity thatmay lead
to CMC in humans.
Candida as a Unique Fungal Commensal in Humans
Candida, Aspergillus and Cryptococcus are the three major opportunistic fungal
species. Candida, especially C. albicans stands out as the most common fungal
pathogen in humans. In healthy individuals, C. albicans adheres to the mucosal ep-
ithelium and skin which is usually symptomless as an established commensalism [24,
25]. In patients with impaired anticandidal host defense, however, these fungi may
cause persistent and recurrent superficial infection and epithelial cell damage which
may be recalcitrant to therapy.
The precise mechanism of commensalism by C. albicans is not completely under-
stood [25, 26]. To establish colonization Candida must have developed the unique
ability to adhere to epithelial cells so that to avoid beingwashed away by food andmu-
cosal secretion. Candida should also be able to compete with other colonizing agents
like bacteria in the gastrointestinal tract. Furthermore,Candida should be able to sur-
vive a large array of host immune and non-immune defenses at mucosal surfaces.
Although the commensal phase itself is generally consideredharmless, itmay develop
into CMC and invasive candidiasis, which is referred to as the pathogenic phase of
C. albicans. Symptomatic damage of the mucosal epithelium is characteristic for the
pathogenic phase, but asymptomatic damage may also occur during the commensal
phase [26, 27].
Candida species “appear to know something” that remains to be elucidated by
scientists searching for a better understanding of host defense against these fungi.
It is intriguing that among the Candida species only a few colonize the mucocuta-
neous surfaces and associate with human disease [27, 28]. C. albicansmay especially
closely associate to humans in contrast to other fungi. Commensal colonization of
Candida is a remarkable conditionbecause thevastmajorityofbothCMCand invasive
Copyright C© Informa Healthcare USA, Inc.
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candidiasis are of endogenous origin [28]. Invasive candidal diseasemay be caused by
various non-albicans Candida like C. glabrata, C. tropicalis and C. parapsilosis. How-
ever, C. albicans is the most common species isolated from patients with CMC. One
possible explanationmaybe thatC.albicans, in contrast to non-albicans species, grow
hyphae that invade andpenetrate epithelial cellsmore aggressively than yeasts. Exper-
imental data suggest that formation of hyphae may be related to virulence of C. albi-
cans and possiblyC. dubliniensiswhich is also known to formhyphae [29].MajorCan-
dida adhesins including hyphal wall protein (Hwp) 1 that binds trans-glutaminase,
and the agglutinin-like sequence (Als) 3 that binds host cell cadherin may play a role
for epithelial binding [30, 31]. That, Candida adhesins may be important to establish
epithelial damage is supported by the observation that deletion of genes encoding
for Hwp1 or Als3 result in remarkable decrease of adhesion to epithelial cells. Other
adhesins on hyphae may recognize arginine-glycine-aspartic acid (RGD) sequences
on epithelial cells and several extracellular matrix proteins [32]. Integrin-like protein
(INT) 1 may recognize RGD-containing proteins. This candidal adhesin is homolo-
gous to mammalian integrins and itself contains an RGD site that may be recognized
by integrins on human cells, facilitating further the adhesion of Candida to the cell
surface [32]. These findings provide further explanation for the unique symbiosis of
Candidawith humans and the tropism of these fungi tomucosal epithelium.Whether
Candida remains a silent and innocent colonizer or becomes an aggressive mucosal
or invasive pathogen depends largely on the ability of the host to mount an efficient
IL-17-mediated effector immunity.
Th17 Cells as Major Players of Host Defense against Candida at Mucosal Surfaces
A subset of CD4+ helper T cells typically produce IL-17A-type cytokines including IL-
17A-E and IL-22 and are referred to asTh17 cells or CD4+IL-17+ T cells [33].Th17 cy-
tokines are important for the prevention of infectionwithCandida colonizing themu-
cocutaneous surfaces [9] (Fig. 1). The differentiation, expansion and maintenance of
human IL-17-producing T cells are induced by a set of cytokines, including IL-1β, IL-
6, IL-21, IL-23 and probably TGF-β, and transcription factors such as STAT3, retinoic
acid-related orphan receptor (ROR)-γ t and interferon regulatory factor 4 [33–37]
(Fig. 1). IL-17A is produced not only by conventional CD4+IL-17+ T helper cells, but
also by γ δ T cells and innate lymphoid cells [38, 39].
Over the past decade our understanding of IL-17+ T lymphocyte-mediated immu-
nity has paralleled with a better understanding of host defense against Candida of
body surfaces. The discovery that CD4+ T cell may be induced by IL-1β and IL-6 to-
ward a CD4+ T cell subset producing IL-17 (CD4+IL17+ cells) opened a new avenue
of intensive research into the pathology of various inflammatory conditions and host
defense mechanisms against Candida [40].
Induction of Th17 Differentiation by Pattern Recognition Receptors
The differentiation of naı¨ve CD4+ T-helper cells into IL-17-producing T cells and the
development of effectivemucosal immunity against fungimay be initiated by binding
of Candida to innate immune cells via pattern recognition receptors (PRRs). These
receptors including toll-like receptor (TLR) 2, TLR4, themacrophagemannose recep-
tor (MR), dectin-1, dectin-2 and the macrophage-inducible C-type lectin (MINCLE)
may bind pathogen-associatedmolecular patterns such as fungalmannoproteins and
β-glucans [41–45].
Recognition ofmannoproteins and glycans by PRRs have been implicated to play a
role in host defense against Candida and innate defense mechanisms were proposed
to shape the adaptive responses by promotion of skewing CD4+ T cells intoTh17 lin-
eage [42, 45, 46]. TLR2 and TLR4 may bind Candida but it was poorly defined how
International Reviews of Immunology
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FIGURE 1. Schematic representation of IL-17+ T cell differentiation and function. The differen-
tiation of naı¨ve CD4+ T cells into CD4+IL-17+ cells is driven by the combined action of cytokines
suchas IL-1β, IL-6, IL-21 and IL-23. Transcription factors, including signal transducer andactivator
of transcription (STAT) 3, retinoic acid-related orphan receptor (ROR) γ t and interferon regulatory
factor (IRF) 4 are also involved in inducing IL-17+ T cell differentiation.The release of IL-17-family
cytokines such as IL-17A/F and IL-22 is a key element of host defense against fungi and bacteria,
because these cytokines induce the secretion of various growth factors, chemokines and antimi-
crobial peptides by epithelial cells.The accumulation of professional phagocytes and antimicrobial
peptides at the site of invasion results in the elimination of fungal and bacterial pathogens. EC, ep-
ithelial cells; G-CSF, granulocyte colony-stimulating factor; PMN, polymorphonuclear neutrophil.
Adapted from [9, 37].
these interactions alter host defense mechanisms [41]. Contradicting data were re-
ported in mice and humans regarding the role of TLR-mediated immunity to Can-
dida and it appears that myeloid differentiation factor (MyD) 88 deficiency do not
predispose humans, in contrast to mice to infections by this fungal pathogen [47, 48].
For example, TLR4 −/− mice exhibited increased susceptibility to invasive candidiasis,
whereas TLR2 −/− mice were more resistant to Candida [49, 50].
The macrophage MR, one of the best characterized C-type lectin receptor (CLR)
was the first membrane receptor implicated in the recognition of Candida yeasts by
humanmacrophages [43, 44, 51–53].Monocyte-derived humanmacrophages (MDM)
ingested and killed unopsonized Candida blastoconidia but both phagocytosis and
killing of unopsonized yeasts were slower than those of serum-opsonized Candida
[42]. Furthermore, unopsonized Candida evoked negligible release of toxic oxygen
radicals compared to the robust generationof these agents by serum-opsonized yeasts
[42].Thesedata suggested that themacrophageMR-mediateduptakeofCandida yeast
could play a role in elimination of these fungi in tissue environments which are poor
Copyright C© Informa Healthcare USA, Inc.
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in opsonising serum such as the subepithelial compartment and body surfaces. Hu-
man blood mononuclear cells could be induced to differentiate into IL-17+ cells by
mannan but not by β-glucan or chitin indicating a role for the MR in shaping IL-
17-mediated immunity [46]. In addition, MR-dependent production of IL-17 by cells
from dectin-1 deficient patients was reported suggesting the role of the MR but not of
dectin-1 in the generation of IL-17 cellular responses [46].Thus, the role that dectin-1
mayplay in defense againstCandida inmice remains to be further defined in humans.
Dectin-2 receptors primarily recognise N-linked mannan exposed on the surface
of Candida and in particular, recognise hyphae rather than yeasts and may be more
relevant innate immune sensors in recognition of Candida than dectin-1 [54]. We be-
lieve that multiple cell-fungal interactionsmay be required to initiate andmount pre-
dominantly Th17 differentiation and the relative role of various PRRs in this complex
immunopathologicalprocess shouldbe the focusof further research.Forexample,pri-
mary deficiency of caspase recruitment domain (CARD) 9 involved in signaling by dif-
ferent lectin receptorswasdescribed ina large Iranian family andwasproposed topre-
dispose patients toCMC [55].However, twoof the eight patients reported in this family
also had invasive candidiasis and two of the patients had no proven candidal disease.
More intriguingly, several patients with invasive infections caused by dermatophytes
but not Candida have been reported recently [56–58]. Thus, the expanding spectrum
of clinical phenotype in patients with CARD9 deficiency makes a direct relationship
between CMC and this PID to be further elucidated.
Inborn Errors of Th17-mediated Immunity in Humans
Experiments in nature suggest that patients with germ linemutations in STAT3 result-
ing in the complex clinical phenotype of hyper-IgE syndrome (HIES), AIREmutation
causingAPS-1 and IL12Rβ1deficiency causing increased susceptibility to atypicalMy-
cobacteriaandSalmonellaare also susceptible toCMC[9–13]. Patientswith thesePIDs
presentwith an impaireddifferentiation of IL17+CD4+Tcells (HIES and IL12Rβ1de-
ficiency) or increased production of anti-IL-17 antibodies (APS-1). STAT1GOFmuta-
tion was also reported to interfere with Th17 differentiation and turned out to be the
most common cause of isolated CMC (CMC disease, CMCD) [14–21]. Sporadic cases
of CMCD caused by germ line mutations of IL17F, IL17RA and ACT1 and character-
ized by impaired stimulus-response coupling and signaling via the IL17R were also
reported [22, 23].
Themilestone discovery of the genetic cause of autosomal dominant HIES
HIES (Job’s syndrome) is a complex PID characterized by skin and lung infections
caused predominantly by Staphylococcus aureus and C. albicans, pneumatocele for-
mation, severe eczema and extreme elevation of serum IgE [10, 59–61]. Distinctive
facial features, hyperextensibility of the joints, cranial synostosis, scoliosis, abnormal
dentition and predisposition to pathological fractures add to the multisystem pheno-
typeofHIES. Staphylococcal skin abscesses typically fail todemonstrate erythemaand
warmth, and hence are called “cold abscesses” [59].
The first breakthrough in our understanding of the role of IL-17-mediated immu-
nity in host defense against Candida of mucocutaneous surfaces was achieved by the
discovery of the genetic basis of HIES. In 2007, two independent groups reportedmu-
tation in STAT3 as amajor cause of autosomal dominant (AD) and sporadic HIES [62,
63]. Mutations were localized in either the DNA-binding domain (DBD) or the SH2
domain of STAT3 but later were described throughout the gene and in different ethnic
groups [64, 65]. SevereTh17 cell depletion was also reported in AD and sporadic HIES
patientswithSTAT3dominantnegativemutation [66–68].Thisobservationwas in con-
International Reviews of Immunology
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cert with the recognition of STAT3 as a transcription factor involved in differentiation
of CD4+ cells into a CD4+IL-17+ lineage (Fig. 1).
STAT3 is a transcription factor involved in signaling for a variety of cytokines, hor-
mones and growth factors which may explain the complex clinical phenotype and
multiple organ involvement in HIES patients [69, 70]. STAT3 plays important roles in
maturation, differentiation and function of T and B cells [71, 72]. In addition to its in-
volvement inTh17 cell differentiation, induction of CD4+ T cells toward the follicular
helper T cell lineage may also depend on STAT3 [73]. Patients with dominant nega-
tive STAT3 mutation present with a decreased number of central memory CD4+ and
CD8+ lymphocytes and an increased number of naı¨ve T cells [74]. Due to this mem-
ory, T cell defect patients with HIES are predisposed to develop varicella zoster virus
reactivation and prolonged Epstein-Barr virus viremia.
The impaired IL-17+ T cell differentiation and function may be a plausible expla-
nation for the susceptibility of HIES patients to CMC [9]. However, such patients are
also susceptible to infections by pyogenic bacteria, especially S. aureus causing re-
current skin and lung infections [37, 60, 61]. Alternative mechanisms responsible for
the unique vulnerability to infection of the skin, mucous membranes and the lung in
HIES patients may exist. In patients with oropharyngeal thrush a significant impaire-
ment in salivary antimicrobial proteins such as β-defensin 2 was found [75, 76]. The
defective salivary gland activity may be related to the reduced candidacidal activity
of saliva and Candida colonization of the mucosa at least in the oropharynx. In addi-
tion, defective responsesof keratinocytes andbronchial epithelial cells to IL-17was re-
ported as a possible additional mechanism responsible for the impaired host defense
to Candida byHIES patients [68]. Cells fromHIES patients weremore dependent than
from healthy controls on the synergistic effect of Th17-derived cytokines and classi-
cal proinflammatory cytokines such as IL-1β in their production of chemokines and
antimicrobial peptides.
Discovery of STAT1 GOFmutation as themost common cause of CMC
The signaling pathway triggered by the engagement of interferons (IFN-γ , IFN-α/β)
and IL-27 with their specific cell surface receptors have been extensively studied
and provided knowledge of the intracellular machinery that include a predominant
activation of STAT1. Loss of function (LOF) mutations in STAT1 were reported to
associate with various infections through mechanisms involving impaired IFN-γ
and IFN-α/β immunity [71, 77]. Complete and partial recessive mutations in STAT1
were described to result in an increased susceptibility to mycobacterial and viral
diseases because of impaired responses to both IFN-γ and IFN-α/β [77]. In contrast,
heterozygous dominant negative mutation in STAT1 cause susceptibility to mild
mycobacterial infection because of impaired response to IFN-γ but not to IFN-α/β.
Recently heterozygousGOFmutation causing impaireddevelopment of IL-17+Tcells
fromCD4+Tcellsweredescribed inpatientswithCMC [14, 15].TheseGOFmutations
resulted in increased phosphorylation, DNA binding, transactivation, and interaction
with protein inhibitor of activated STAT (PIAS), and decreased dephosphorylation of
STAT1 [14, 78]. Thus, the poor development of IL-17+ T cells, and as a consequence
CMC may involve increased responses to IFN-γ , IFN-α/β and IL-27, which are
STAT1-dependent repressors of IL-17-producing cells. STAT1GOFmutation was first
discovered by whole-exome sequencing in a Ukrainian patient with CMCD [14, 35].
CCD and DBD mutations were subsequently found in a large number of patients in
other kindreds [14–21]. Over the past few years, GOF mutations of STAT1 have been
proved to be themost common etiology of CMC.Heterozygous dominant STAT1GOF
mutationmay lead to stronger cellular responses to STAT1-dependent IL-17 inhibitors
Copyright C© Informa Healthcare USA, Inc.
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(IFN-α/β, IFN-γ and IL-27) [14]. This would account for the impaired IL-17+ T-cell
development with an impact on IL-17+ T cell-mediated antifungal responses.
Infectious etiologies which were also described in association with STAT1 GOF
mutation include Histoplasma capsulatum, Coccidioides immitis, Apophysomyces
trapeziformis, orf virus, Penicillium marneffei and Fusarium solani [17, 78–82]. Pa-
tients with STAT1 GOF mutations may display herpes reactivation diseases in addi-
tion to CMCD [17].The recurrent herpes virus disease observed in some patients with
such mutations may be due to the impaired development and maintenance of cen-
tral memory T cells, as in patients with heterozygous STAT3mutations and AD HIES
[83].
Deficient functioning of the IFN-γ /IL-12 pathway was found to associate with
invasive infection by dimorph endemic fungi like Histoplasma capsulatum and
Coccidioides immitis [84, 85]. Five patients with STAT1 GOF mutation were also
identified with invasive histoplasmosis and CMC (3 patients) and coccidioidomyco-
sis without CMC (2 patients) [78].The heterozygous missense mutations affecting the
CCDorDBDof STAT1 resulted in lower STAT1methylation, enhanced STAT1/protein
inhibitor of activated STAT1 (PIAS) association, increased IFN-γ -induced gene ex-
pression, and impaired responses to IFN-γ restimulation.This report and other stud-
ies suggested the intriguing possibility of functional overlap of GOF and LOF muta-
tions of STAT1.
STAT1 GOF mutation has been identified in a 24-year-old male patient with dis-
seminated mucormycosis caused by Apophysomyces trapesiformis [79]. This patient
never had CMCor autoimmunity and he had no predisposing condition tomucormy-
cosis, such as penetrating trauma, diabetes mellitus or hemochromatosis. Thus, A.
trapesiformis and othermembers of theMucorales speciesmay cause infections in pa-
tients with STAT1GOFmutation. Mucormycosis may be a heralding infectious mani-
festation of this genetic disorder before the occurrence of CMC.
A 34-year-old male patient with a previous history of recurrent and persistent can-
didiasis of the skin, nails, and mucosal surfaces starting at 2 years of age developed
orf, a viral zoonotic disease, caused by Parapoxvirus [80]. Genetic analysis of this
patient and his 6-year-old son who had been also suffering from CMC since birth,
revealed heterozygous c.820G>A STAT1 mutation (R274W). This mutation was pre-
viously found to result in STAT1GOF including enhanced phosphorylation andDNA-
binding, and impaireddifferentiationofCD4+Tcells into IL-17+ cells [14, 17]. In con-
trast to other patients carrying the R274Wmutation the index patient (but not his son)
also had severe CD4 lymphopenia, low levels of IgG2 and IgG4 subclasses and recur-
rent bacterial pneumonias since 15 years of age. He was treated with regular IVIG in-
fusions.The giant orf lesion on his handwas successfully curedwith cidofovir. His dis-
ease course was complicated with Coombs positive hemolytic anemia, autoimmune
hepatitis, hypothyroidism and pulmonary embolia. Despite successful hematopoietic
stem cell transplantation performed at age 35 he died because of bleeding from an in-
tracranial mycotic aneurism, a well-defined complication in patients with CMC [14,
21]. It remains unclear whether impairedTh17 immunity played any role in the devel-
opment of orf in this patient.This report nevertheless raises the possibility that STAT1
GOFmutationmay predispose toDNA viral disease other than recurrent varicella and
HSV, described before in two patients also carrying the R274Wmutation [17].
STAT1 GOF mutation associated with CMC and invasive infection by Penicillium
marneffeywas reported in three Chinese patients [81]. Lymphocytes from two of these
patients exhibited defective IFN-γ production upon stimulation with P. marneffey in
vitro. The authors suggested that the combined primary defect in IFN-γ an IL-17 im-
mune responses may be responsible for infection by this filamentous mold. This re-
port further extends the spectrum of infections occurring in patients in STAT1 GOF
International Reviews of Immunology
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mutation. It also suggests that the phenotypic expression of STAT1GOFmutationmay
be wider than it was previously thought.
Another chronic fungal infections associated with a previously described STAT1
GOFmutationwas found in a Chinese patients with infection by Fusarium solani [82].
This patient was free of CMCor invasive candidal disease.This report further confirms
the possibility that STAT1 GOF mutation may predispose patients to a wide range of
infections including various fungal disease.
Predisposition to CMC in patients with IL12Rβ1 and IL-12p40 deficiency
IL-12 and IL-23 areheterodimeric cytokines composeof p35andp19 subunits, respec-
tively, and share a p40 subunit [86, 87].Thedisulphide-bond 35 kDand 40 kD subunits
of IL-12 produced primarily by professional antigen presenting cells bind to the IL-12
Rβ1/IL-12Rβ2 receptor complex [88]. IL-12 induces the production of IFN-γ by NK
cells and T cells (Fig. 2) and drive CD4+ T cells to differentiate into Th1 phenotype
[88, 89]. High-affinity binding of IL-12 to its receptor requires both IL-12Rβ1 and IL-
12Rβ2 chains but gene expression studies suggested that the IL-12Rβ1 is primarily
responsible for IL-12 binding whereas IL-12Rβ2 is mediating signaling [88]. On the
other hand, the p19–p40 heterodimer of IL-23 also binds to IL-12Rβ1 but not to the β2
chain and uses its own receptor complex composed of IL-12Rβ1 and IL-23R on T cells
and NK cells [90, 91]. IL-23 is a key cytokine to maintain expansion of CD4+IL17+ T
cells that differentiate from naı¨ve CD4+ cells upon exposure to IL-1β, IL-6 and IL-21
[33, 92]. Unsurprisingly, the functional impairment of IL-12Rβ1 was found to result in
a wide range of infections caused predominantly by intracellular pathogens [93–98].
T cells and NK cells from patients with IL-12Rβ1mutation cannot respond to IL-12 or
IL-23 because these cytokines bind to IL-12Rβ1 and these patients frequently develop
CMC [11]. T cells and NK cells from patients with deficiency of the IL-12p40 subunit
shared by IL-12 and IL-23 may also be susceptible to CMC because of the impaired
maintenance of IL17+ T cells at mucosal surfaces. In contrast, patients with various
genetic forms IFN-γR deficiency do not display CMC [93]. Instead, they present with
Mendelian susceptibility to mycobacterial disease.
Analyses of 156 patients with IL-12Rβ1 deficiency showed that 35 (23%) of such
patients presented with clinical features of candidiasis [11]. Most patients were iden-
tified with recurrent and persistent CMC and candidiasis was the first documented
clinical manifestation in 19 of 35 patients despite vaccination of 10 of these 19 pa-
tients with live bacille Calmette-Gue´rin vaccine. Most candidiasis episodes were mu-
cocutaneous, oropharyngeal candidiasis being the most common, with esophageal,
cutaneous and genital candidiasis also being recorded. In addition to mucosal or cu-
taneous fungal diseases, five episodes of invasive candidiasis affecting four patients
were found. Intriguingly, in some patients the first episodes of candidiasis occurred
before mycobacterial disease or salmonellosis were documented.
CMC was also observed in 3 (6.7%) of 49 patients with autosomal recessive IL-
12p40 deficiency [12]. One patient had invasive candidiasis and two presented with
oral thrush. The immunological basis of the remarkably lower incidence of CMC in
patients with IL-12p40 deficiency compared to that found in patients with IL-12Rβ1
deficiency is not completely understood.
Revealing germ-line IL17F, IL17RA and ACT1mutations in patients with CMCD
The binding of IL-17A and IL-17F to their receptors induces diverse signaling path-
ways and results in the secretion of antimicrobial peptides, tumor necrosis fac-
tor (TNF)-α, IL-6, IL-8, CXCL-1, CCL20, granulocyte colony-stimulating factor (G-
CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) [99–102].
These cytokines and chemokines recruit and activate polymorphonuclear neutrophil
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FIGURE 2. Schematic representation of the interleukin (IL)-12/interferon (IFN) γ circuit. Upon
ingestionof pathogensbymononuclear phagocytes (MNP), dentritic cells (DCs) IL-12 and IL-23 are
produced, which in turn will induce the production of IFN-γ by natural killer (NK) cells and CD4+
T cells. IL-18 also induces the release of IFN-γ byNK cells andT cells. IFN-γ binds to its cell-surface
receptor that consists of twoheterodimeric subunits IFNγRα (or IFNGR1) and IFNγRβ (or IFNGR2)
chains, which are coupled with Janus-associated kinase (JAK) 1 and JAK2. IFN-γ binding results in
dimerization of the two receptor subunits and phosphorylation of JAK1 and JAK2. Activated JAKs
phosphorylate IFNGR1 leading to recruitment and activation of signal transducer and activator of
transcription (STAT) 1 proteins that translocate to the nucleus and binds to interferon-gamma-
activated sequences (GAS) of IFN-γ -inducible genes which are then transcribed. Adapted from
[9].
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FIGURE 3. Schematic representation of the IL-17/ IL-17R coupling and IL17R-mediated sig-
naling. IL-17A and IL-17F heterodimers or homodimers are recognized by the plasma mem-
brane (PM)-localized IL-17RA/IL-17RC heteromeric receptor complex. Upon ligand binding,
IL-17R will recruit the adaptor molecule NF-κB activator (ACT) 1 by homotypical interactions
between their respective SEFIR domains. TRAF6 and TAK1 binding in turn will activate the
IKK complex and induce NF-κB activation. ACT1 may also associate with IKKi and subse-
quently activate TRAF2 and TRAF5. SEFIR, similar expression to fibroblast growth factor (SER)/IL-
17R domain; TRAF, tumor necrosis factor receptor-associated factor; IKK, inhibitor of NF-κB
kinase; IKKi, inducible IKK; TAK, transforming growth factor beta-activated kinase. Adapted
from [9].
granulocytes, providing protection against diverse infectious agents in the environ-
ment (Fig. 1). Downstream signaling activated by IL-17R binding to its ligands include
the adaptor protein ACT1 [100–103]. IL-17A and IL-17F form heterodimers and ho-
modimers and signal through a heteromeric receptor complex of two IL-17R chains:
IL-17RAand IL-17RC(Fig. 3) [101, 103]. Receptor ligandcouplingwill subsequently re-
sult in recruitment of ACT1 [104]. Both IL-17R chains and ACT1 contain a conserved
SEFIR domain and binding of these proteins occurs via homotypical interactions be-
tween their respective SEFIR domains (Fig. 3). The E3 ubiquitine ligase TRAF6 binds
then toACT1 andmediates downstream signaling [103–105]. Ubiquitination of TRAF6
byACT1will trigger recruitment of TAK1 and the TAK1binding partnermolecules and
induceNF-κB activation (Fig. 3). ACT1may also form a complexwith the inducible ki-
nase IKKi which will phosphorylate ACT1 and generate docking sites for the adaptors
TRAF2 and TRAF5 [100, 102].
The most compelling evidence that isolated CMC is truly a PID was provided by
analyses of patientswith recurrent or persistentCandida infections andAD IL-17Fde-
ficiency or autosomal recessive IL-17RA deficiency [22]. One of the published cases, a
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Moroccanboy,wasborn to consanguineousparents andwas found to carry ahomozy-
gous c.850C> Tmutation in the IL17RA gene, resulting in the creation of a premature
stop codon (Q284X) in the part of the gene corresponding to the extracellular domain
of the receptor.Thismutation abolished responses to IL-17A and IL-17F, due to a com-
plete loss of IL-17RAprotein expression on the patient’s cells.Theparents and siblings
of this patient were all healthy and heterozygous for this mutation [22].
The other patients, from amultiplex Argentinean family, had a c.284C>T heterozy-
gous mutation in the IL17F gene, predicting the replacement of serine residue with a
leucine residue in position 65. This mutation was shown to be severely hypomorphic
and dominant, as it affected the function of both homo- and heterodimers containing
themutant isoform,by impairing their binding to the receptor [22].Theseobservations
clearly support the concept that CMCdiseasemay occur as a result of inborn errors of
IL-17-mediated immunity.
Biallelic missense mutation in the adaptor protein ACT1 and CMC in two siblings
was reported [106].The T536I mutation affected the SEFIR domain and abolished ho-
motypic interaction between ACT1 and the IL-17R chains. This mutation also abol-
ished responses of patients’ fibroblasts to IL-17A and IL-17F and of T cells to IL-17E.
In contrast to SEFIR-dependent interactions, binding of ACT1 to other proteins like
CD40, heat shock protein (HSP) 70 and HSP90 remained intact.
CONCLUSION
C. albicans is a unique commensal atmucosal surfaces in humans and several PRRs of
innate immune cells were implicated in binding Candida yeasts and hyphae. In par-
ticular, the role of PRRs in inducingTh17 cell differentiation fromnaı¨veCD4+ cells has
been proposed but the precise mechanism of IL-17 induction has only been vaguely
defined. Until the discovery of STAT3 dominant negativemutation causing severe de-
fect ofTh17 cell differentiation, our understanding of themechanisms involved inhost
mucosal responses in humans to Candida was poor. Recent advances in our under-
standing of genetic etiologies of several PIDs such as STAT3mutation in patients with
AD and sporadic HIES, and STAT1 GOF mutation causing CMCD elucidated signif-
icantly our knowledge of anticandidal immunity of mucosal surfaces. Discoveries of
IL17F, IL17RA andACT1mutations in associationwithCMCDenlightened further the
mechanisms underlying CMC in patients with PIDs and have revealed that human IL-
17+ T-cell immunity is critical for mucocutaneous host defense against Candida in
natural conditions. More research is required to define precisely the mechanisms by
which IL-17+T cells contribute to the elimination of candidal and bacterial infections
at body surfaces. Such studies should take into account the disease-modifying factors
responsible for the severity and variability of the phenotypes of PIDs associated with
IL-17+ T cell-mediated immune defects.
ABBREVIATIONS
ACT NF-κB activator
AD autosomal dominant
Als agglutinin-like sequence
APS autoimmune polyendocrine syndrome
AR autosomal recessive
CARD caspase recruitment domain
CCD coiled-coil domain
CLR C-type lectin receptor
CMC mucocutaneous candidiasis
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CMCD CMC disease
DC dentritic cell
DBD DNA-binding domain
EC epithelial cell
G-CSF granulocyte colony-stimulating factor
GM-CSF granulocyte-macrophage colony-stimulating factor
GOF gain of function
HIES hyper-IgE syndrome
Hwp hyphal wall protein
HSP heat-shock protein
IFN interferon
IKK inhibitor of NF-κB
IKKi inducible IKK
IL interleukin
INT integrin-like protein
IRF interferon regulatory factors
ISRE interferon-stimulated response element
JAK Janus-associated kinase
LOF loss-of-function
MDM monocyte-derived macrophage
MINCLE macrophage-inducible C-type lectin
MR mannose receptor
NF-κB nuclear factor kappa B
NK natural killer
MyD myeloid differentiation factor
PAMP pathogen-associated molecular pattern
PIAS protein inhibiting activated STAT1
PID primary immunodeficiency disorder
PMN polymorphonuclear neutrophil
PRR pattern recognition receptor
RGD arginine-glycine-aspartic acid
ROR retinoic acid-related orphan receptor
SEFIR similar expression to fibroblast growth factor (SER)/IL-17R domain
STAT signal transducer and activator of transcription
TAK transforming growth factor beta-activated kinase
TLR Toll-like receptor
TNF tumor necrosis factor
TRAF TNF receptor associated factor
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